AAPL343.91-3.82 (-1.10%) ▼|ABBV286.74+1.10 (+0.39%) ▲|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|AAPL343.91-3.82 (-1.10%) ▼|ABBV286.74+1.10 (+0.39%) ▲|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|
17.7 C
New York
Tuesday, October 27, 2026

Tag: patient

Accuray to Report Fourth Quarter Fiscal 2025 Financial Results on August 13, 2025

MADISON, Wis., July 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2025, ended...

Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug – Hagens Berman

SAN FRANCISCO, July 30, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise acquired Replimune (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025.

Sharecare to collaborate with Centers for Medicare & Medicaid Services to improve care quality, accelerate progress in healthcare

Company doubles down on its commitment to transform personal health journey of every American at invitation-only Health Tech Ecosystem event at the White House
Company doubles down on its commitment to transform personal health journey of every American at invitation-only Health Tech Ecosystem event at the White House

Everads Announces Two Oral Presentations at ASRS 2025, Including Full Clinical Trial Results with Its Novel Suprachoroidal Injector

– Clinical study confirms safety, feasibility, and tolerability of the Everads Injector– – Preclinical data demonstrate the feasibility of in-office, minimally invasive suprachoroidal buckling using...

ARCHIMED Acquires a Majority Stake in Arkstone, Forging a Powerful Partnership to Accelerate Global Healthcare Innovation And Dominate the Emerging AI-Driven Clinical Decision Support...

Arkstone, an innovative biotechnology company democratizing infectious disease expertise and fighting antimicrobial resistance, has been acquired by global healthcare private equity firm ARCHIMED, which...

b.well Connected Health Commits to Being a CMS-Aligned Network, Validating Decade-Long Vision for True Healthcare Interoperability

b.well's FHIR-based infrastructure, semantic interoperability capabilities, and consumer-centered user experience align with CMS's vision for modern healthcare data exchange BALTIMORE, July 30, 2025 /PRNewswire/ --...

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company’s significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.

Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis

– Nuvisertib (TP-3654), an oral investigational highly selective PIM-1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – MARLBOROUGH, Mass.,...

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

The Pankey Institute’s Annual Symposium to be Held September 18-20, 2025 in Palm Beach, Florida

This Year's Theme, "Harmony in Interdisciplinary Care: Blending Expertise," Celebrates True Collaboration in Patient-Centered Dentistry KEY BISCAYNE, Fla., July 30, 2025 /PRNewswire/ -- The Pankey...

OncoHost Named Top Precision Oncology Solution for 2025

BINYAMINA, Israel and CARY, N.C., July 30, 2025 /PRNewswire/ -- OncoHost, a leader in precision oncology leveraging proteomics and AI to personalize cancer care, today...

Subtle Medical Among First to Achieve ISO/IEC 42001:2023 Certification for AI Management

The certification reinforces the company's leadership in AI safety, efficacy, and ethical governance. MENLO PARK, Calif., July 30, 2025 /PRNewswire/ -- Subtle Medical, a global...

NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement.

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient